Literature DB >> 1731002

Technetium-99m-DTPA aerosol and gallium-67 scanning in pulmonary complications of human immunodeficiency virus infection.

J Rosso1, J M Guillon, A Parrot, M Denis, G Akoun, C Mayaud, M Scherrer, M Meignan.   

Abstract

We retrospectively compared the results of 67Ga chest scans and 99mTc-DTPA aerosol clearance measurements with those of fiberoptic bronchoscopy in 88 patients infected with the human immunodeficiency virus. Of 100 investigations, a pulmonary infection was diagnosed in 39, mainly Pneumocystis carinii pneumonia and a noninfectious disorder was found in 42, mainly Kaposi's sarcoma and lymphocytic alveolitis. Gallium scans and DTPA clearance were abnormal respectively in 74% and 92% of infectious complications, and in 12% and 60% of noninfectious disorders. In 10 cases, DTPA clearance was accelerated, while chest x-ray, arterial blood gases and even gallium scanning were normal. A value of DTPA clearance greater than 4.5%.min-1 was both sensitive and specific for the diagnosis of Pneumocystis carinii pneumonia. The gallium scan was always normal in bronchopulmonary Kaposi's sarcoma. We conclude that in symptomatic patients: (1) DTPA clearance measurements are useful for detecting lung disease when chest x-ray and/or PaO2 are normal and (2) a gallium scan is indicated to distinguish progressive Kaposi's sarcoma from a superimposed second process when radiological abnormalities of pulmonary Kaposi's sarcoma are present.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731002

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  Simultaneously evaluating the effects of one-week fluticasone propionate inhalation therapy on lung ventilation and permeability in children with asthma.

Authors:  A C Chen; F J Tsai; C H Tsai; C C Lin; C C Lee; C H Kao
Journal:  Lung       Date:  2003       Impact factor: 2.584

Review 2.  AIDS and the lung: update 1995. 3. Intrathoracic Kaposi's sarcoma in patients with AIDS.

Authors:  J Cadranel; C Mayaud
Journal:  Thorax       Date:  1995-04       Impact factor: 9.139

3.  HIV in the lung: guilty or not guilty?

Authors:  C M Mayaud; J Cadranel
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

4.  Detection of acute inhalation injury in fire victims by means of technetium-99m DTPA radioaerosol inhalation lung scintigraphy.

Authors:  W Y Lin; C H Kao; S J Wang
Journal:  Eur J Nucl Med       Date:  1997-02

5.  A pilot trial of quantitative Tc-99m HMPAO and Ga-67 citrate lung scans to detect pulmonary vascular endothelial damage and lung inflammation in patients of collagen vascular diseases with active diffuse infiltrative lung disease.

Authors:  L W Hang; W H Hsu; J J P Tsai; Y F Jim; C C Lin; A Kao
Journal:  Rheumatol Int       Date:  2003-06-28       Impact factor: 2.631

6.  Evaluation of alveolar permeability and lung ventilation in patients with chronic renal failure using Tc-99m DTPA radioaerosol inhalation lung scintigraphy.

Authors:  C H Kao; Y H Hsu; S J Wang
Journal:  Lung       Date:  1996       Impact factor: 2.584

Review 7.  Pulmonary technetium-99m diethylene triamine penta-acetic acid aerosol clearance as an index of lung injury.

Authors:  M J O'Doherty; A M Peters
Journal:  Eur J Nucl Med       Date:  1997-01

Review 8.  Clinical studies of alveolar-capillary permeability using technetium-99m DTPA aerosol.

Authors:  F X Sundram
Journal:  Ann Nucl Med       Date:  1995-11       Impact factor: 2.668

Review 9.  Radionuclide Imaging of Fungal Infections and Correlation with the Host Defense Response.

Authors:  Alfred O Ankrah; Mike M Sathekge; Rudi A J O Dierckx; Andor W J M Glaudemans
Journal:  J Fungi (Basel)       Date:  2021-05-22

10.  Influence of hilar deposition in the evaluation of the alveolar epithelial permeability on 99mTc-DTPA aerosol inhaled scintigraphy.

Authors:  Shigeyuki Ogi; Eisuke Gotoh; Mayuki Uchiyama; Kunihiko Fukuda; Mitsuyoshi Urashima; Nobuyoshi Fukumitsu
Journal:  Jpn J Radiol       Date:  2009-02-08       Impact factor: 2.374

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.